Geminor M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, resulting in effective reduction of blood glucose levels in patients inadequately controlled by diet and exercise alone. Geminor M 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to assess therapeutic response and adjust dosage accordingly. Caution is advised in patients with renal impairment, hepatic dysfunction, or risk factors for lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and weight gain. This medication should be used under medical supervision, with periodic evaluation of renal function and metabolic parameters to ensure safety and efficacy.